Skip to main content

Day: September 17, 2020

Quorum Announces Sponsorship of the TADA Innovation Series & Expo

DealerMine CRM, Autovance and Quorum DMS will have staffed booths in the virtual exhibit hallAutovance’s digital retailing will be showcased in the event’s demo theatreCALGARY, Alberta, Sept. 17, 2020 (GLOBE NEWSWIRE) — Quorum Information Technologies Inc. (TSX Venture: QIS) (“Quorum” or the “Corporation”), announced today their sponsorship of the Trillium Auto Dealers Association’s (TADA) first virtual event, the Auto Dealers Innovation Series & Expo (ADIS), to occur next Thursday, September 24th.The event will include industry speakers, unique prize and networking opportunities, over 20 exhibitors and a demo theatre that will showcase vendors presenting the latest and greatest tools and technologies transforming the automotive retail industry. Dealers can attend from the comfort of their own desks.The...

Continue reading

Trevali Announces Annual General Meeting Results

VANCOUVER, British Columbia, Sept. 17, 2020 (GLOBE NEWSWIRE) — Trevali Mining Corporation (“Trevali” or the “Company”) (TSX: TV, BVL: TV; OTCQX: TREVF, Frankfurt: 4TI) announced the voting results from its Annual General Meeting of Shareholders (the “Meeting”) held on September 16, 2020. Shareholders voted in favour of all items of business before the Meeting as follows:Detailed voting results for the Meeting are available on SEDAR at www.sedar.com.About Trevali Mining CorporationTrevali is a global base-metals mining company, headquartered in Vancouver, Canada. The bulk of Trevali’s revenue is generated from base-metals mining at its three operational assets: the 90%-owned Perkoa Mine in Burkina Faso, the 90%-owned Rosh Pinah Mine in Namibia, and the wholly-owned Santander Mine in Peru. In addition, Trevali owns the Caribou Mine,...

Continue reading

Zynerba Pharmaceuticals Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion Syndrome

DEVON, Pa., Sept. 17, 2020 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration has granted orphan drug designation for cannabidiol (CBD) for use in treating 22q11.2 deletion syndrome (22q). 22q is a rare midline condition featuring physical abnormalities and debilitating neuropsychiatric and behavioral symptoms including anxiety, withdrawn behavior, and social interaction problems.“Zynerba is committed to developing Zygel™ CBD gel in certain rare and near-rare conditions, including 22q, for which there is an urgent need for new, innovative therapeutics,” said Armando Anido, Chairman and Chief Executive Officer of Zynerba. “We...

Continue reading

Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial

– Study Met Primary Endpoint of Reduction of Time to Recovery– Additional Analyses Ongoing to Understand Other Clinical Outcome Data– Lilly’s Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Baricitinib ContinuesTORONTO, Sept. 17, 2020 (GLOBE NEWSWIRE) — On Monday, September 14th, Eli Lilly and Company and Incyte announced initial data emerging from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). ACTT-2 included more than 1,000 patients and began on May 8 to assess the efficacy and safety of a 4-mg dose of baricitinib plus remdesivir versus remdesivir in hospitalized patients with COVID-19.Baricitinib in combination with remdesivir met the primary endpoint of reduction of...

Continue reading

Le baricitinib en association avec le remdésivir réduit le temps de guérison chez les patients hospitalisés atteints de la COVID-19 et participant à l’étude ACTT-2 commanditée par le NIAID

– L’étude a satisfait au critère d’évaluation principal, soit la réduction du temps de guérison– Des analyses supplémentaires sont en cours dans le but de comprendre la portée d’autres données sur les résultats cliniques– Lilly poursuit son étude de phase III à répartition aléatoire, à double insu et contrôlée par placebo sur le baricitinibTORONTO, 17 sept. 2020 (GLOBE NEWSWIRE) — Le lundi 14 septembre, Eli Lilly and Company et Incyte ont annoncé le dévoilement des premières données recueillies dans le cadre de l’étude sur le traitement adaptatif de la COVID-19 (ACTT-2) commanditée par le National Institute of Allergy and Infectious Diseases (NIAID), lequel fait partie des National Institutes of Health (NIH). L’ACTT-2, une étude portant sur plus de 1 000 patients, a commencé le 8 mai à évaluer l’efficacité et l’innocuité d’une dose...

Continue reading

Agenus to Participate in Webcast Hosted by William Blair on ESMO2020 Results and Novel Pipeline

LEXINGTON, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) — Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. David O’Malley, expert in gynecologic oncology, and members of Agenus’ management team will participate in a webcast hosted by Dr. Matt Phipps of William Blair on Monday September 21, 2020 at 2:30 p.m. ET.Dr. David O’Malley will review data of balstilimab as a monotherapy and in combination with zalifrelimab presented at ESMO from the largest clinical trials of IO therapies in refractory cervical cancer, and he will discuss the potential of this proprietary combination.  Members of the Agenus management team will be available to discuss the next steps...

Continue reading

MGP Names Sarah Corwin Principal Scientist

ATCHISON, Kan., Sept. 17, 2020 (GLOBE NEWSWIRE) — Sarah Corwin, PhD, RD, has been named Principal Scientist for MGP Ingredients (Nasdaq: MGPI), a leading provider of specialty wheat proteins and starches. A PhD graduate in Food Science at Purdue University, Corwin completed her doctoral dissertation on slow-digesting carbohydrates, which will help support MGP’s research into the physiological benefits of dietary fiber in humans.At Purdue, Corwin managed the Carbohydrate Chemistry Laboratory and participated in numerous professional development activities provided by food and baking industry organizations, including the American Society of Baking (ASB) product development committee and as a volunteer with the Institute of Food Technologists (IFT) Carbohydrate Division Leadership. She also was an officer of The Cereals and Grains...

Continue reading

Dealnet Recommends Shareholders Tender to Premium Cash Offer from Simply Green

Simply Green’s Offer was by far the highest bid in a comprehensive strategic review processCash Offer is at a premium of 93% to the 90-day VWAP on the TSX-V for the period ending August 21, 2020TORONTO, Sept. 17, 2020 (GLOBE NEWSWIRE) — Dealnet Capital Corp. (“Dealnet” or the “Company“) (TSX VENTURE: DLS) reminds shareholders to tender their Dealnet common shares (the “Common Shares”) by October 14, 2020 to the premium cash offer of $0.16 per Common Share (the “Offer”) from Simply Group Acquisition Corp. (“Simply Green”) which commenced on September 9, 2020 through the mailing of a take-over bid circular to Dealnet shareholders.The Offer represents a premium of 33% to the closing price of the Common Shares on the TSX Venture Exchange (the “TSX-V”) on August 21, 2020 (the last trading day prior to the announcement...

Continue reading

Casa Systems Powers Distributed Access Architecture Momentum with New Gen 2 Nodes and Multiple Virtual CCAP Wins

Mediacom Communications first to deploy new Casa Systems DA2200 nodes as part of its 10G Smart Home, demonstrating the cable industry’s vision for future gigabit connectivity and symmetrical servicesANDOVER, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) — Casa Systems, Inc. (Nasdaq: CASA), a leading provider of cloud-native, virtual and physical infrastructure technology solutions for mobile, cable and fixed telco networks, today announced the launch of its Distributed Access Architecture (DAA) Gen 2 nodes – the DA2200 and the DA1250 – key additions to the company’s next-gen cable infrastructure solutions that also include its virtual CCAP (vCCAP) that is now deployed with customers in North America and China. In combination, these solutions provide an open, web-scale, converged platform to deliver multi-services over a fiber-deep network...

Continue reading

YANGAROO Grants Stock Options

TORONTO, Sept. 17, 2020 (GLOBE NEWSWIRE) — YANGAROO Inc. (“Yangaroo”, “Company”), (TSX-V: YOO, OTCBB: YOOIF), the software leader in work-flow management and media distribution solutions, is pleased to announce a grant of stock options (the “Options”) in accordance with the terms and conditions of the Company’s Stock Option Plan to certain directors of the Company, to purchase an aggregate of 70,000 common shares in the capital stock of the Company.The Options are exercisable for a period of five years from the date of grant at a price of $0.105 per share. Following 10% of the Options vesting on the date of grant, the remaining 90% will vest as to a third on each 6-month anniversary following the date of grant.Subject to acceptance by the TSX Venture Exchange, this grant of options will result in a total of 6,952,500 options issued...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.